Mallinckrodt (Mallinckrodt) Debt-to-Revenue : 0.19 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Mallinckrodt Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Mallinckrodt's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $377 Mil. Mallinckrodt's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0 Mil. Mallinckrodt's annualized Revenue for the quarter that ended in Sep. 2023 was $1,988 Mil. Mallinckrodt's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 was 0.19.

Mallinckrodt Debt-to-Revenue Historical Data

The historical data trend for Mallinckrodt's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mallinckrodt Debt-to-Revenue Chart

Mallinckrodt Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Revenue

Get a 7-Day Free Trial

1.89

1.70

1.62

0.63

N/A

Mallinckrodt Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Revenue	Get a 7-Day Free Trial															1.40	1.57	1.82	1.63	0.19

Competitive Comparison of Mallinckrodt's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mallinckrodt's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mallinckrodt's Debt-to-Revenue falls into.

Mallinckrodt Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Mallinckrodt's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(44.1	+	3027.7)	/	N/A
	=	N/A

Mallinckrodt's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(377.4	+	0)	/	1988
	=	0.19

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2023) Revenue data.

Mallinckrodt Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Mallinckrodt (Mallinckrodt) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MCKPF) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15

Website

https://www.mallinckrodt.com

Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.

Executives

Alta Fundamental Advisers Llc	10 percent owner	1500 BROADWAY, SUITE 704, NEW YORK NY 10036
Jason Daniel Goodson	officer: EVP & Head of Corp Development	106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885
James R Sulat	director
Paul Bisaro	director
Sigurdur O Olafsson	director, officer: President and CEO	360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Stephen Andrew Welch	officer: EVP & Head of Spec Generics	18440 BRIDGEMORE LANE, LOUISVILLE KY 40245
Peter C Richardson	officer: EVP & Chief Scientific Officer	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Susan Michele Silbermann	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lisa French	officer: EVP & Chief Commercial Officer	301 CONTINENTAL LANE, PAOLI PA 19301
Mark Anthony Tyndall	officer: EVP & Chief Legal Offi & Secre	1101 Q ST NW, WASHINGTON DC 20009
Henriette Nielsen	officer: EVP & Chief Transformation OFC	202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024
Karen Ling	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Olifant Luxco S.a R.l.	10 percent owner	19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Paul Rutherford Carter	director	SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF